JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Rhythm Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

111.76 -1.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

110.45

Max

115.63

Belangrijke statistieken

By Trading Economics

Inkomsten

2.9M

-47M

Verkoop

16M

49M

Winstmarge

-96.144

Werknemers

283

EBITDA

6.9M

-40M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+5.36% upside

Dividenden

By Dow Jones

Volgende Winsten

4 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.5B

7.4B

Vorige openingsprijs

113.66

Vorige sluitingsprijs

111.76

Nieuwssentiment

By Acuity

75%

25%

346 / 373 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 okt 2025, 23:32 UTC

Populaire aandelen

Stocks to Watch: Amazon, Reddit, SPS Commerce

30 okt 2025, 23:02 UTC

Winsten

AIA Group 3Q Value of New Business Grew

30 okt 2025, 23:45 UTC

Marktinformatie

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30 okt 2025, 23:00 UTC

Winsten

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30 okt 2025, 22:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

30 okt 2025, 22:59 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30 okt 2025, 22:56 UTC

Marktinformatie

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30 okt 2025, 22:35 UTC

Winsten

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30 okt 2025, 22:35 UTC

Winsten

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30 okt 2025, 22:31 UTC

Winsten

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30 okt 2025, 22:29 UTC

Winsten

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30 okt 2025, 22:27 UTC

Winsten

Minas Buenaventura 3Q EPS 66c >BVN

30 okt 2025, 22:27 UTC

Winsten

Minas Buenaventura 3Q Rev $431M >BVN

30 okt 2025, 22:27 UTC

Winsten

Minas Buenaventura 3Q Net $179M >BVN

30 okt 2025, 22:16 UTC

Marktinformatie
Winsten

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30 okt 2025, 22:14 UTC

Winsten

Review & Preview: A Tech Earnings Storm -- Barrons.com

30 okt 2025, 22:00 UTC

Winsten
Acquisities, Fusies, Overnames

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30 okt 2025, 21:39 UTC

Winsten

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 okt 2025, 21:26 UTC

Winsten

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 okt 2025, 21:14 UTC

Marktinformatie
Winsten

Apple Sees Record Quarterly Services Revenue -- Market Talk

30 okt 2025, 21:09 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

30 okt 2025, 21:09 UTC

Marktinformatie
Winsten

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30 okt 2025, 21:04 UTC

Winsten

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30 okt 2025, 21:03 UTC

Winsten

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30 okt 2025, 21:03 UTC

Winsten

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold Skouries on Track for 1Q of 2026

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q Adj EPS 41c >EGO

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q Rev $434.7M >EGO

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q Net $56M >EGO

30 okt 2025, 21:00 UTC

Winsten

Eldorado Gold 3Q EPS 27c >EGO

Peer Vergelijking

Prijswijziging

Rhythm Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

5.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 120 USD  5.36%

Hoogste 142 USD

Laagste 95 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rhythm Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

13

Buy

0

Hold

0

Sell

Technische score

By Trading Central

60 / 65.58Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

346 / 373 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat